Skip to main content


Findings from an open label cohort study showed treatment of moderate to severe hidradenitis suppurativa with an IL-17 inhibitor was associated clinical response and had a favorable safety profile.
Findings from a recent study showed that satisfaction with physicians is associated with mental health comorbidities among patients with psoriasis.
Understanding the dermatologic signs of COVID-19 will help elucidate whether pernio-toes, papulovesicular lesions, retiform purpura, or another underreported manifestation are legitimate diagnostic features of the disease.
Guidance Released on the Management of Cutaneous Lymphoma During the Pandemic; The Skin Cancer Foundation Awards Research Grants; Minority Populations Less Aware of Melanoma; Childhood BMI Significantly Associated with HS Risk
A recent meta-analysis and systematic review investigated the effectiveness of systemic treatments for patients with atopic dermatitis, highlighting 2 with potentially better short-term efficacy.
Findings from a recent study showed a potential association between birth weight and childhood weight and the risk of developing hidradenitis suppurativa in adulthood.
A recent study investigated the efficacy of ixekizumab for the treatment of moderate to severe pityriasis rubra pilaris, which showed promising results for the inhibition of IL-17 in this disease.
Findings from a recent study showed no association between the use of topical tacrolimus and cancer among pediatric patients with atopic dermatitis.
The United States Lymphoma Consortium released recommendations for the treatment of patients with cutaneous lymphoma during the COVID-19 pandemic.
Using data from a large registry, researchers investigated the real-world safety of several systemic medications including etanercept, secukinumab, ustekinumab, and apremilast.
Back to Top